{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:15:19Z","timestamp":1781918119440,"version":"3.54.5"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Importance<\/jats:title>\n            <jats:p>Ovarian, fallopian tube, and primary peritoneal cancers constitute the deadliest gynecologic malignancies. After primary cytoreductive surgery, there are several standard first-line cytotoxic treatments for providers to consider. Newer molecular targeted therapies are becoming more common and may have a role as first-line therapy in the future.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This article provides an evidence-based review of all approved standard therapies for first-line treatment of advanced-stage, high-grade serous ovarian cancer. Treatment schedules, dose modifications, and drug substitutions are reviewed. Ongoing trials and pending approvals for newer molecular therapies are discussed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Evidence Acquisition<\/jats:title>\n            <jats:p>A comprehensive primary literature review was performed using MEDLINE, the Cochrane Collaborative Database, and PubMed. Guidelines from the National Comprehensive Cancer Network and the Society for Gynecologic Oncology were also reviewed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seven different approved first-line regimens for high-grade serous ovarian cancer are available based on literature review. These vary in route of administration, dose intensity, drug combinations, and treatment schedules. Molecular targeted therapies, including antiangiogenic drugs and poly(ADP-ribose) polymerase inhibitors, have also been studied in multiple randomized controlled trials in the first-line setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions and Relevance<\/jats:title>\n            <jats:p>Cytotoxic regimens remain the foundation of first-line treatment for high-grade serous ovarian cancer. Choosing which regimen is best for a patient depends on both patient and disease factors. Molecular therapies in first-line treatment are a promising and exciting possibility, with regulatory approval pending.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Target Audience<\/jats:title>\n            <jats:p>Obstetricians and gynecologists, family physicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Learning Objectives<\/jats:title>\n            <jats:p>After completing this activity, the learner should be better able to compare the 7 approved up-front cytotoxic regimens for high-grade serous ovarian cancer; choose a regimen based on patient and disease factors; and distinguish 3 molecular therapies that are in clinical trials that may be incorporated into up-front therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ogx.0000000000000613","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T23:29:44Z","timestamp":1542324584000},"page":"650-657","source":"Crossref","is-referenced-by-count":17,"title":["Current First-line Therapy for Ovarian Cancer: A Comprehensive Review"],"prefix":"10.1097","volume":"73","author":[{"given":"Stuart R.","family":"Pierce","sequence":"first","affiliation":[{"name":"Fellow and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie H.","family":"Clark","sequence":"additional","affiliation":[{"name":"Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230930","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"suppl 1","key":"bib2-20230930","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"bib4-20230930","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2014.12.018","article-title":"Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification","volume":"136","year":"2015","journal-title":"Gynecol Oncol"},{"key":"bib5-20230930","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004347-199010000-00006","article-title":"Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma","volume":"9","year":"1990","journal-title":"Int J Gynecol Pathol"},{"key":"bib6-20230930","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.09.023","article-title":"Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel\/carboplatin chemotherapy: cell type is the most useful prognostic factor","volume":"48","year":"2012","journal-title":"Eur J Cancer"},{"key":"bib7-20230930","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib8-20230930","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib9-20230930","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"bib10-20230930","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2007.09.035","article-title":"High frequency of BRCA1\/2 germline mutations in consecutive ovarian cancer patients in Poland","volume":"108","year":"2008","journal-title":"Gynecol Oncol"},{"key":"bib11-20230930","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","year":"2015","journal-title":"Cancer Discov"},{"key":"bib12-20230930","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","article-title":"A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study","volume":"57","year":"1986","journal-title":"Cancer"},{"key":"bib13-20230930","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study","volume":"7","year":"1989","journal-title":"J Clin Oncol"},{"issue":"5 suppl 12","key":"bib14-20230930","first-page":"40","article-title":"Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III\/IV ovarian cancer (from the Gynecologic Oncology Group)","volume":"23","year":"1996","journal-title":"Semin Oncol"},{"key":"bib15-20230930","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib16-20230930","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3747\/co.v18i2.725","article-title":"Phase ii\/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21","volume":"18","year":"2011","journal-title":"Curr Oncol"},{"key":"bib18-20230930","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"143","year":"2016","journal-title":"Gynecol Oncol"},{"key":"bib19-20230930","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jnci\/djj443","article-title":"Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments","volume":"98","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"bib22-20230930","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib23-20230930","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"bib24-20230930","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2016.11.033","article-title":"Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer\u2014an NRG Oncology\/Gynecologic Oncology Group study","volume":"144","year":"2017","journal-title":"Gynecol Oncol"},{"key":"bib25-20230930","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","year":"2014","journal-title":"Pain"},{"key":"bib26-20230930","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"bib27-20230930","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib28-20230930","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00685842","article-title":"Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines","volume":"32","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"bib29-20230930","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","year":"2013","journal-title":"Cancer Res"},{"key":"bib30-20230930","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"bib31-20230930","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","year":"2013","journal-title":"Lancet Oncol"},{"key":"bib32-20230930","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib33-20230930","first-page":"18","article-title":"929O_PRICON8: a GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian\/fallopian tube\/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib34-20230930","first-page":"3380","article-title":"Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy","volume":"49","year":"1989","journal-title":"Cancer Res"},{"key":"bib35-20230930","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","year":"1996","journal-title":"N Engl J Med"},{"key":"bib36-20230930","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","year":"2001","journal-title":"J Clin Oncol"},{"key":"bib37-20230930","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"bib38-20230930","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib39-20230930","first-page":"208","article-title":"A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG Oncology study","volume":"141","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"Suppl 15","key":"bib40-20230930","first-page":"5502","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","year":"2014","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"key":"bib41-20230930","first-page":"1363","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib42-20230930","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2011.07.016","article-title":"Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study","volume":"123","year":"2011","journal-title":"Gynecol Oncol"},{"key":"bib43-20230930","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2008.12.035","article-title":"An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer","volume":"113","year":"2009","journal-title":"Gynecol Oncol"},{"key":"bib44-20230930","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","year":"2012","journal-title":"J Clin Oncol"},{"key":"bib45-20230930","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib46-20230930","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib47-20230930","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","article-title":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study","volume":"139","year":"2015","journal-title":"Gynecol Oncol"},{"key":"bib48-20230930","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"bib49-20230930","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["Obstetrical &amp; Gynecological Survey"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006254-201811000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:03:39Z","timestamp":1696053819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006254-201811000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ogx.0000000000000613","relation":{},"ISSN":["1533-9866","0029-7828"],"issn-type":[{"value":"1533-9866","type":"electronic"},{"value":"0029-7828","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}